Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens
Abstract
We compared neutralizing antibody responses to BA.4/5, BQ.1.1, XBB, and XBB.1.5 Omicron severe acute respiratory syndrome coronavirus 2 variants after a bivalent or ancestral coronavirus disease 2019 (COVID-19) messenger RNA booster vaccine or postvaccination infection. We found that the bivalent booster elicited moderately high antibody titers against BA.4/5 that were approximately 2-fold higher against all Omicron variants than titers elicited by the monovalent booster. The bivalent booster elicited low but similar titers against both XBB and XBB.1.5 variants. These findings inform risk assessments for future COVID-19 vaccine recommendations and suggest that updated COVID-19 vaccines containing matched vaccine antigens to circulating divergent variants may be needed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 06, 2023
- Source ID
- 10.1093/infdis/jiad111
Entities
People
- Carol D Weiss
- Edward Mitre
- Emilie Goguet
- Russell Vassell
- Simon Pollett
- Stephanie Paz
- Wei Wang
Organizations
- Defense Health Agency
- Food and Drug Administration
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- National Institute of Allergy and Infectious Diseases
- Uniformed Services University of the Health Sciences
- United States Department of Defense